翰思艾泰-B(03378)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03378 翰思艾泰-B

未开盘 01-13 16:08:11

16.970

+0.020

+0.12%

最高17.200	最低16.860	成交量14.45万
今开16.950	昨收16.950	日振幅2.01%
总市值23.12亿	流通市值23.12亿	总股本1.36亿
成交额245.60万	换手率0.11%	流通股本1.36亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03378","market":"HK","secType":"STK","nameCN":"翰思艾泰-B","latestPrice":16.97,"timestamp":1768291691841,"preClose":16.95,"halted":0,"volume":144500,"delay":0,"floatShares":136218830,"shares":136218830,"eps":-0.918,"marketStatus":"未开盘","change":0.02,"latestTime":"01-13 16:08:11","open":16.95,"high":17.2,"low":16.86,"amount":2456035,"amplitude":0.020059,"askPrice":16.97,"askSize":23600,"bidPrice":16.87,"bidSize":2600,"shortable":0,"etf":0,"ttmEps":-1.222,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768354200000},"marketStatusCode":0,"adr":0,"listingDate":1766419200000,"exchange":"SEHK","adjPreClose":16.95,"openAndCloseTimeList":[[1768267800000,1768276800000],[1768280400000,1768291200000]],"volumeRatio":0.7528394285175538,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000905","market":"SZ","secType":"STK","nameCN":"厦门港务","latestPrice":13.93,"timestamp":1768287600000,"preClose":14.15,"halted":0,"volume":74921500,"delay":0,"premium":"+8.91"}},"requestUrl":"/m/hq/s/03378","defaultTab":"news","newsList":[{"id":"2601193178","title":"厦门港务：拟61.78亿元购买集装箱码头集团70%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2601193178","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601193178?lang=zh_cn&edition=full","pubTime":"2026-01-06 18:43","pubTimestamp":1767696203,"startTime":"0","endTime":"0","summary":"人民财讯1月6日电，厦门港务(000905)1月6日公告，拟发行股份及支付现金购买厦门国际港务有限公司（简称“国际港务”）持有的厦门集装箱码头集团有限公司（简称“集装箱码头集团”）70%股权。交易价格为61.78亿元，其中现金对价9.27亿元，股份对价52.51亿元。同时，拟向不超过35名特定对象募集配套资金不超过35亿元，用于厦门港多式联运智慧物流中心项目、码头设备更新改造项目、翔安港区1#—5#集装箱泊位工程项目、支付本次交易现金对价、补充流动资金等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106185622a6fa1cb5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106185622a6fa1cb5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1173","03378","BK1535"],"gpt_icon":1},{"id":"2601193158","title":"翰思艾泰-B01月06日遭主力抛售51.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601193158","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601193158?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:15","pubTimestamp":1767687352,"startTime":"0","endTime":"0","summary":"01月06日, 翰思艾泰-B股价跌0.12%，报收16.93元，成交金额333.5万元，换手率0.14%，振幅5.31%，量比0.22。翰思艾泰-B今日主力资金净流出51.0万元，上一交易日主力净流出50.6万元。该股近5个交易日上涨16.36%，主力资金累计净流出414.9万元；近20日主力资金累计净流出414.9万元，其中净流出天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106162108a6f9747e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106162108a6f9747e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1535","BK1173","03378"],"gpt_icon":0},{"id":"2601001547","title":"翰思艾泰-B01月05日主力净流出50.6万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2601001547","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601001547?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:15","pubTimestamp":1767600945,"startTime":"0","endTime":"0","summary":"01月05日, 翰思艾泰-B股价跌0.64%，报收16.95元，成交金额614.5万元，换手率0.27%，振幅8.68%，量比0.30。翰思艾泰-B今日主力资金净流出50.6万元，上一交易日主力净流入6.0万元。该股近5个交易日下跌2.53%，主力资金累计净流出363.9万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出363.9万元，其中净流出天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105162025a49e1693&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105162025a49e1693&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03378","BK1173","BK1535"],"gpt_icon":1},{"id":"2600105455","title":"翰思艾泰-B01月02日主力净流入6.0万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2600105455","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600105455?lang=zh_cn&edition=full","pubTime":"2026-01-02 16:15","pubTimestamp":1767341729,"startTime":"0","endTime":"0","summary":"01月02日, 翰思艾泰-B股价涨6.76%，报收17.06元，成交金额1226.2万元，换手率0.55%，振幅11.95%，量比0.21。翰思艾泰-B今日主力资金净流入6.0万元，上一交易日主力净流出97.4万元。该股近5个交易日下跌0.81%，主力资金累计净流出313.4万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出313.4万元，其中净流出天数为2日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102161644a4942074&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102161644a4942074&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1173","03378","BK1535"],"gpt_icon":0},{"id":"2595223487","title":"翰思艾泰-B12月31日主力净流入112.7万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2595223487","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595223487?lang=zh_cn&edition=full","pubTime":"2025-12-31 16:15","pubTimestamp":1767168918,"startTime":"0","endTime":"0","summary":"12月31日, 翰思艾泰-B股价涨9.60%，报收15.98元，成交金额980.7万元，换手率0.47%，振幅13.92%，量比0.00。翰思艾泰-B今日主力资金净流入112.7万元，上一交易日主力净流出97.4万元。该股近5个交易日下跌50.06%，主力资金累计净流出206.6万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出206.6万元，其中净流出天数为2日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231161608a6e4b0fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231161608a6e4b0fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03378","BK1173","BK1535"],"gpt_icon":1},{"id":"2595886754","title":"厦门港务：购买厦门集装箱码头集团70%股权事项获深交所审核通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2595886754","media":"财闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595886754?lang=zh_cn&edition=full","pubTime":"2025-12-30 08:58","pubTimestamp":1767056310,"startTime":"0","endTime":"0","summary":"12月30日，厦门港务早间公告，公司拟通过发行股份及支付现金的方式向厦门国际港务有限公司购买其持有的厦门集装箱码头集团有限公司70%股权，并向不超过35名符合条件的特定对象发行股份募集配套资金。深交所并购重组审核委员会于12月29日召开会议，对公司此次交易的申请进行了审议。本次交易尚需中国证券监督管理委员会同意注册后方可实施。本次交易最终能否完成注册，以及最终取得注册的时间均存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230085912a487e850&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230085912a487e850&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1535","BK1173","03378"],"gpt_icon":0},{"id":"2595783331","title":"翰思艾泰-B12月29日主力净流出222.0万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2595783331","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595783331?lang=zh_cn&edition=full","pubTime":"2025-12-29 16:15","pubTimestamp":1766996158,"startTime":"0","endTime":"0","summary":"12月29日, 翰思艾泰-B股价跌16.33%，报收14.55元，成交金额2196.1万元，换手率1.04%，振幅17.08%，量比0.00。该股近5个交易日下跌54.63%，主力资金累计净流出222.0万元；近20日主力资金累计净流出222.0万元，其中净流出天数为1日。该股主力净额占比0.11%，港股市场排名2640/2703。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229162224a4853b54&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229162224a4853b54&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03378","BK1173","BK1535"],"gpt_icon":0},{"id":"2595420107","title":"港股异动 | 翰思艾泰-B(03378)跌超13% 较招股价已腰斩 总市值约20亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595420107","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595420107?lang=zh_cn&edition=full","pubTime":"2025-12-29 13:50","pubTimestamp":1766987404,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，翰思艾泰-B跌超13%，盘中低见15.05港元再创新低，较招股价32港元已跌超50%。截至发稿，跌13.4%，报15.06港元，成交额1744.68万港元，总市值20.61亿港元。值得注意的是，翰思艾泰的管线均未实现商业化。财务方面，2023年、2024年及2025年前8个月，翰思艾泰期内亏损分别为8516.0万元、1.17亿元、8743.8万元。截至2025年10月31日，现金及其等价物为1.33亿元，流动负债总额为2.2亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1535","03378","BK1173"],"gpt_icon":0},{"id":"1136212543","title":"异动解读 | 翰思艾泰-B盘中大跌13.11%，上市后持续承压，临床管线风险引担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1136212543","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136212543?lang=zh_cn&edition=full","pubTime":"2025-12-29 11:02","pubTimestamp":1766977346,"startTime":"0","endTime":"0","summary":"翰思艾泰-B今日盘中大跌13.11%，延续了其上市以来的疲软表现。消息面上，翰思艾泰-B自12月23日登陆港股以来表现不佳，上市首日即暴跌46.25%，市值缩水至约20亿元人民币。翰思艾泰-B的研发投入有限，却选择了CD47这一高难度靶点，而全球尚无同类药物成功获批。叠加公司短期内难以商业化的预期，市场对其长期价值持谨慎态度，导致股价持续承压。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03378"],"gpt_icon":0},{"id":"2594266410","title":"厦门港务12月25日获融资买入1.35亿元，融资余额4.77亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2594266410","media":"新浪财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594266410?lang=zh_cn&edition=full","pubTime":"2025-12-26 12:48","pubTimestamp":1766724503,"startTime":"0","endTime":"0","summary":"两融数据显示，当日厦门港务获融资买入额1.35亿元，融资偿还1.25亿元，融资净买入930.79万元。截至12月25日，厦门港务融资融券余额合计4.79亿元。融资方面，厦门港务当日融资买入1.35亿元。截至9月30日，厦门港务股东户数4.18万，较上期减少20.04%；人均流通股17738股，较上期增加25.06%。分红方面，厦门港务A股上市后累计派现10.04亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251226125249a6d12b97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251226125249a6d12b97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1535","BK1173","03378"],"gpt_icon":1},{"id":"2594263689","title":"185 万血汗钱一夜蒸发！血泪控诉！HSAT国配惨遭“ 大 V” 收割","url":"https://stock-news.laohu8.com/highlight/detail?id=2594263689","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594263689?lang=zh_cn&edition=full","pubTime":"2025-12-26 11:09","pubTimestamp":1766718540,"startTime":"0","endTime":"0","summary":"　　转发自路边社小作文$翰思艾泰-B$. 　　无良大 V 利用我对他的信任，短短 2 天我的血汗钱蒸发了 185 万。　　用我血与泪的教训告诉大家，不要参与任何与这个骗子大 V瞪羚社 Kris.Z 杨泽康有关的任何项目．。　　利用信任、大 V 身份以及信息不对等骗你入场，并要求 55 分账，给到翻倍预期；承诺给大V最低风险，带兄弟吃肉。　　利用多年好友的信任，以及“医药大 V”的身份、“上市翻倍”的预期，骗取我们参与这一场精心设计的骗局：","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-12-26/doc-inheautu1243984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1535","SINA","03378","BK1173"],"gpt_icon":1},{"id":"2594284633","title":"翰思艾泰港交所上市首日大跌30%！5.9亿港元融资押注肿瘤免疫与ADC创新药，HX009领衔多管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2594284633","media":"摩熵医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594284633?lang=zh_cn&edition=full","pubTime":"2025-12-25 12:00","pubTimestamp":1766635251,"startTime":"0","endTime":"0","summary":"图源：摩熵医药数据库-全球药物研发数据库公司的定位是提供新一代肿瘤免疫治疗，如HX009、HX044及HX016，以对抗PD-1抗性；提供一流的ADC分子HX111，以精确治疗特定恶性肿瘤；以及提供新型自身免疫治疗，如BsAb双功能抗体HX035及HX038。2023年、2024年和2025年前八个月，翰思艾泰研发开支分别为人民币4,666.3万、7,472.1万和5,617.8万元；净亏损分别为人民币0.85亿、1.17亿和0.88亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225120125a475e3b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225120125a475e3b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1173","BK1535","BK1161","06978","03378","BK1574"],"gpt_icon":1},{"id":"2593477604","title":"市值近44亿港元，光谷又诞生一家上市公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2593477604","media":"长江日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593477604?lang=zh_cn&edition=full","pubTime":"2025-12-24 19:53","pubTimestamp":1766577186,"startTime":"0","endTime":"0","summary":"12月23日，翰思艾泰生物医药科技（武汉）股份有限公司在港交所成功上市，成为光谷第71家上市公司。本次IPO，翰思艾泰全球发售1832.1万股，发行价为32港元每股，募资总额5.86亿港元，发行市值近44亿港元。截至目前，光谷境内外上市公司总数达71家，上市公司数量超过全市60%，约占全省1/3。在生命健康领域，光谷已有9家上市公司。目前光谷有6家公司进入上市审核程序，19家公司启动IPO辅导，2025年入库金种子公司209家，上市后备梯队持续扩充。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224212935a6ca9711&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224212935a6ca9711&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1173","BK1535","03378"],"gpt_icon":1},{"id":"2593942679","title":"冰与火之歌：宝济药业(02589)180%暴涨vs华芢生物(02396)、翰思艾泰(03378)腰斩 港股生物科技新股极端分化启示录","url":"https://stock-news.laohu8.com/highlight/detail?id=2593942679","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593942679?lang=zh_cn&edition=full","pubTime":"2025-12-24 12:47","pubTimestamp":1766551655,"startTime":"0","endTime":"0","summary":"2025年12月，港股IPO市场上演了一场令人瞠目结舌的“冰与火之歌”。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20251224/20251224125033_33927.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251224/20251224125033_33927.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385346.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02659","BK1233","BK1535","159837","BK1587","BK1616","02589","BK1173","03378","02396"],"gpt_icon":1},{"id":"1148803609","title":"异动解读 | 翰思艾泰-B盘中大涨5.23%，创新药HX111获批临床试验提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1148803609","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148803609?lang=zh_cn&edition=full","pubTime":"2025-12-24 09:36","pubTimestamp":1766540183,"startTime":"0","endTime":"0","summary":"翰思艾泰-B今日盘中大涨5.23%，引起了市场的广泛关注。消息面上，公司开发的创新药注射用HX111已获中国国家药品监督管理局批准开展临床试验。HX111为首创OX40靶向抗体偶联药物，临床前研究显示，OX40在若干恶性肿瘤中相较于正常组织呈过度表达，成为ADC的合适靶点。翰思艾泰-B是一家专注于新一代免疫疗法开发的生物科技公司，此前已通过港股18A规则上市。HX111是公司继HX009及HX044两项双特异性抗体疗法后，推进至临床开发的第三个首创分子。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03378"],"gpt_icon":0},{"id":"2593418386","title":"翰思艾泰-B(03378)获批准于中华人民共和国开展注射用HX111临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2593418386","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593418386?lang=zh_cn&edition=full","pubTime":"2025-12-23 21:12","pubTimestamp":1766495577,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B 发布公告，由本公司开发的创新药注射用HX111已获中华人民共和国国家药品监督管理局批准于中华人民共和国境内开展临床试验。HX111为首创OX40靶向抗体偶联药物。临床前研究表明，OX40为肿瘤相关抗原，于若干恶性肿瘤中相较于正常组织呈过度表达，因而成为如HX111等ADC方式的合适靶点。HX111为本公司继HX009及HX044两项FIC双特异性抗体疗法后，推进至临床开发的第三个首创分子。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1535","03378","BK1173"],"gpt_icon":1},{"id":"2593492943","title":"3000倍超购换来首日暴跌近50%，翰思艾泰-B(03378)何以成为打新“陷阱”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2593492943","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593492943?lang=zh_cn&edition=full","pubTime":"2025-12-23 19:46","pubTimestamp":1766490417,"startTime":"0","endTime":"0","summary":"继12月22日华生物-B首挂当日股价收跌近30%后，12月23日首挂上市的翰思艾泰-B同样受到市场“暴击”。根据发行计划，此次翰思艾泰全球发售1832.1万股H股。从财务表现来看，2023年、2024年及2025年前8个月，翰思艾泰期内亏损分别为8516.0万元、1.17亿元、8743.8万元。截至2025年10月31日，现金及其等价物为1.33亿元，流动负债总额为2.2亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1535","03378","BK1173"],"gpt_icon":1},{"id":"2593491216","title":"光谷，又一家生物企业敲钟上市！","url":"https://stock-news.laohu8.com/highlight/detail?id=2593491216","media":"IVD资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593491216?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:43","pubTimestamp":1766482984,"startTime":"0","endTime":"0","summary":"来源：中国光谷12月23日，翰思艾泰生物医药科技（武汉）股份有限公司在港交所成功上市，成为光谷第71家上市公司。翰思艾泰上市敲钟现场翰思艾泰成立于2014年，专注研发用于癌症及自身免疫疾病精准治疗的创新药。截至目前，公司拥有10款候选药物管线，其中3款处于临床阶段、7款处于临床前阶段。翰思艾泰生物成立于2014年，是一家专注于结构生物学、转化医学及临床开发的创新型生物科技公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223185350a46e9c49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223185350a46e9c49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03378","BK1173","BK1535"],"gpt_icon":1},{"id":"2593639194","title":"武汉又冲出一个医药IPO！60岁武大学霸带队","url":"https://stock-news.laohu8.com/highlight/detail?id=2593639194","media":"创业邦","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593639194?lang=zh_cn&edition=full","pubTime":"2025-12-23 11:23","pubTimestamp":1766460221,"startTime":"0","endTime":"0","summary":"翰思艾泰正在研发用于癌症及自身免疫疾病精准治疗的创新药，解决该领域未被满足的医疗需求。01湖北农村走出的IPO敲钟人现年60岁的张发明，出生在湖北天门石家河镇的一个普通农村家庭，16岁时考入武汉大学物理化学专业，是家中第一个走出乡村的大学生。以此为平台，张发明正式进军创新药研发。HX009是一款PD-1/SIRPα双功能抗体融合蛋白，其设计旨在同时阻断PD-1免疫抑制信号和CD47-SIRPα介导的免疫逃逸信号，从而协同激活T细胞和巨噬细胞，对抗肿瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223112437a6c409fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223112437a6c409fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1515","BK1574","03378","BK1173","BK1161","BK1535"],"gpt_icon":1},{"id":"2593946824","title":"港股不行了？今天这家新药上市又是大跌30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593946824","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593946824?lang=zh_cn&edition=full","pubTime":"2025-12-23 10:47","pubTimestamp":1766458020,"startTime":"0","endTime":"0","summary":"2025年12月23日，湖北武汉的翰思艾泰生物科技(武汉)股份有限公司在港交所上市，大跌30%。本次发行1832.1万股，发行价32港元/股，规模约5.9亿港元（约合7500万美元）。公司有核心产品HX009（PD-1/SIRPα双功能抗体融合蛋白）、两款主要产品HX044及HX301，还有7项临床前阶段候选药物。其定位是提供新一代肿瘤免疫治疗、一流ADC分子及新型自身免疫治疗。2023年、2024年和2025年前八个月，公司研发开支分别为4666.3万、7472.1万和5617.8万元，净亏损分别为0.85亿、1.17亿和0.88亿元。文中未提及投资机构、财务顾问及融资目的。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223110617a46cf17e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223110617a46cf17e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03378","BK1173","BK1535"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hanxbio.com/","stockEarnings":[{"period":"1week","weight":0.0024},{"period":"1month","weight":-0.4697},{"period":"ytd","weight":0.062}],"compareEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.0336},{"period":"3month","weight":0.0362},{"period":"6month","weight":0.0959},{"period":"1year","weight":0.4225},{"period":"ytd","weight":0.0475}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"翰思艾泰生物医药科技（武汉）股份有限公司是一家主要从事肿瘤免疫疗法的研发的中国公司。该公司的产品管线有针对肿瘤学的临床阶段候选药物和临床前阶段候选药物，包括核心产品HX009及主要产品HX301及HX044，以及针对自身免疫和肿瘤市场的抗体偶联药物、双特异性抗体及单克隆抗体。HX009是一种自主研发的抗程序性细胞死亡蛋白1（PD-1）/信号调节蛋白α（SIRPα）双功能抗体融合蛋白。HX301是一种靶向集落刺激因子-1受体（CSF1R）、AMPK相关蛋白激酶5（ARK5）、FMS样酪氨酸激酶3（FLT-3）及细胞周期蛋白依赖性激酶4/6（CDK4/6）等关键通路的多靶点激酶抑制剂。HX044为一种新型双重功能抗细胞毒性T淋巴细胞相关蛋白4（CTLA-4）抗体SIRPα融合蛋白。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.005427},{"month":2,"riseRate":0.411765,"avgChangeRate":0.008835},{"month":3,"riseRate":0.352941,"avgChangeRate":-0.021319},{"month":4,"riseRate":0.705882,"avgChangeRate":0.100651},{"month":5,"riseRate":0.352941,"avgChangeRate":0.046508},{"month":6,"riseRate":0.470588,"avgChangeRate":-0.00883},{"month":7,"riseRate":0.470588,"avgChangeRate":0.004276},{"month":8,"riseRate":0.470588,"avgChangeRate":-0.031033},{"month":9,"riseRate":0.588235,"avgChangeRate":-0.013577},{"month":10,"riseRate":0.75,"avgChangeRate":0.019136},{"month":11,"riseRate":0.625,"avgChangeRate":0.009468},{"month":12,"riseRate":0.625,"avgChangeRate":0.056179}],"exchange":"SEHK","name":"翰思艾泰-B","nameEN":"HANXBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰思艾泰-B(03378)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰思艾泰-B(03378)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰思艾泰-B,03378,翰思艾泰-B股票,翰思艾泰-B股票老虎,翰思艾泰-B股票老虎国际,翰思艾泰-B行情,翰思艾泰-B股票行情,翰思艾泰-B股价,翰思艾泰-B股市,翰思艾泰-B股票价格,翰思艾泰-B股票交易,翰思艾泰-B股票购买,翰思艾泰-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰思艾泰-B(03378)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰思艾泰-B(03378)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}